Exegiline Pharma Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Core Technology
BiologicalsMolecules
Tags (10)
drug-developmentparkinsonoral-drugspharma-companiesneurologybrain-disordertreatmentsdegenerative-diseasespharmaceuticalsalzheimers-disease
Exegiline Pharma Financials
Undisclosed
Capital raised
Cumulative Funding Raised Over Time ($)
Exegiline Pharma Lifecycle
Cumulative Funding Raised Over Time
Exegiline Pharma News
1 article
In Parkinson's Awareness Month, Parkinson's pioneer wins Israel Prize
Youdim Pharmaceuticals, led by Prof. Emeritus Moussa Youdim and his son Tal Youdim, is making significant strides in developing treatments for neurodegenerative diseases such as Parkinsons and Alzheimers. The company has developed innovative drugs and devices, including the Endopump and multitarget drug MT-031. The Endopump, a streamlined drug delivery device, has shown promising results in animal studies and is set to enter the next stage of development with a major medical device company. Additionally, MT-031 aims to treat dementia and depression in neurodegenerative patients. The company is currently fundraising $5-10 million for preclinical trials. Moussa Youdim was recently awarded the 2022 Israel Prize in Life Sciences for his groundbreaking work.
InvestmentPartners
Exegiline Pharma Team
Tal Youdim
Chairman
Founder
Dr. Santiago Ini
CEO
Founder
Prof. Moussa Youdim
Founder
Founder
Prof. Eli Heldman
CSO, Director
Founder
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.